Jin, Shuting
Zeng, Xiangxiang
Fang, Jiansong
Lin, Jiawei
Chan, Stephen Y.
Erzurum, Serpil C.
Cheng, Feixiong
Funding for this research was provided by:
Foundation for the National Institutes of Health (K99HL138272, R00HL138272)
Article History
Received: 24 April 2019
Accepted: 10 September 2019
First Online: 13 November 2019
Competing interests
: S.Y.C. has served as a consultant for Zogenix, Vivus, Aerpio, and United Therapeutics; S.Y.C. is a director, officer, and shareholder in Numa Therapeutics; S.Y.C. holds research grants from Actelion and Pfizer. S.Y.C. has filed patent applications regarding the targeting of metabolism in pulmonary hypertension.